Orexigen Therapeutics to Present at Upcoming Conferences

SAN DIEGO, May 8, 2012 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences. The details are as follows:

The 11th Annual JMP Securities Research Conference
Date: May 15, 2012
Time: 4:00pm Pacific Time
Location: Ritz-Carlton, San Francisco
Speaker: Michael Narachi, President and Chief Executive Officer

Bank of America Merrill Lynch 2012 Health Care Conference
Date: May 17, 2012
Time: 10:40am Pacific Time
Location: Encore at Wynn Las Vegas
Speaker: Michael Narachi, President and Chief Executive Officer

To listen to the live webcast or a replay of the presentations, please visit the Investor Relations section of the company's Web site at www.orexigen.com. A replay will be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave®, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment for the Contrave cardiovascular outcomes trial which the company plans to initiate this quarter. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.

Orexigen Contact:

Media Contact:       

McDavid Stilwell

Denise Powell

VP, Corporate Communications and Business Development

WCG

(858) 875-8629

(510) 703-9491

SOURCE Orexigen Therapeutics, Inc.



RELATED LINKS
http://www.orexigen.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.